HRPC(SH:600829)2017-10-19 16:00Financial Performance - Operating revenue for the period was CNY 6,238,323,344.15, representing a decline of 5.52% year-on-year[7] - Net profit attributable to shareholders was CNY 208,158,766.40, an increase of 7.27% compared to the same period last year[7] - Basic and diluted earnings per share were both CNY 0.3590, reflecting a growth of 7.26%[7] - The company’s net profit for the year is not expected to incur significant losses or major changes compared to the previous year[16] - Total operating revenue for the first nine months of 2017 was CNY 6,238,323,344.1, a decrease of 5.5% compared to the same period last year[26] - Net profit attributable to the parent company for the first nine months of 2017 was CNY 208,158,766.40, an increase of 7.2% compared to the same period last year[27] - The company reported a gross profit margin of approximately 4.0% for the first nine months of 2017[26] - The total profit for Q3 2017 was CNY 2,516,188.70, down from CNY 2,977,542.97 in Q3 2016, representing a decrease of 15.5%[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,664,151,404.15, a decrease of 3.03% compared to the end of the previous year[7] - Total assets decreased to ¥4,664,151,404.15 from ¥4,810,079,828.61, reflecting a decline in current and non-current assets[21] - Total liabilities decreased to ¥3,098,160,435.04 from ¥3,162,303,327.40, indicating a reduction in financial obligations[22] - Total assets as of the end of the reporting period amounted to CNY 1,318,600,006.37, a decrease from CNY 1,605,190,951.13 at the end of the previous period[25] - Total liabilities were CNY 35,105,007.26, down from CNY 35,777,425.82 in the previous period[25] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 25,647,303.84, an improvement from a net outflow of CNY 147,219,695.51 in the same period last year[7] - The company's cash flow from operating activities for the first nine months of 2017 was CNY 5,987,630,005.28, an increase from CNY 5,641,001,260.39 in the same period last year[33] - The net cash flow from operating activities for Q3 2017 was -25,647,303.84 RMB, an improvement from -147,219,695.51 RMB in the same period last year[34] - Total cash outflow from operating activities was 6,013,277,309.12 RMB, compared to 5,788,220,955.90 RMB in Q3 2016[34] - The total cash outflow from operating activities for the first nine months was 20,850,836.34 RMB, compared to 52,544,340.55 RMB in the same period last year[37] Shareholder Information - The total number of shareholders at the end of the reporting period was 18,286[10] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., held 74.82% of the shares[10] Government and Other Income - Government subsidies recognized in the current period amounted to CNY 1,449,888.87, contributing to the overall financial performance[9] - Non-recurring gains and losses totaled CNY 1,624,216.22 for the current period[9] Expenses - Operating tax and additional fees increased by 51.64% to ¥21,743,599.18 compared to ¥14,338,890.09 in the same period last year[15] - Financial expenses surged by 763.41% to ¥10,950,540.60 due to increased discount interest on receivables and new loan interest expenses[15] - The company incurred sales expenses of CNY 183,295,891.66 for the first nine months, an increase of 16.4% year-over-year[26] - The company’s financial expenses for the first nine months were CNY 10,950,540.60, significantly higher than CNY 1,268,296.4 in the previous period[26] Future Plans - The company has plans for market expansion and new product development in the upcoming quarters[27] - The company is currently planning a significant asset restructuring, which has led to a suspension of its stock trading since October 19, 2017[15]